Medad Technology launches NEB Mist ultrasound nicotine delivery device after extensive consumer trials
Laboratory tests conducted by UK and EU health regulators detect no traces of carcinogenic agents
Dubai, UAE: UAE tech company Medad Technology has launched an alternative to tobacco and e-cigarettes that produces no detectable carcinogenic agents, according to independent tests conducted by medical experts in the United Kingdom and the United States.
Now available in the UAE, the company’s innovation – NEB Mist – uses its patented ultrasound technology to aerosolize a liquid containing pharmaceutical-grade nicotine into a mist – unlike standard electronic nicotine delivery systems (ENDS), and other reduced risk alternatives to tobacco smoking, which rely on electronic heating elements such as heated coils to create a vapour.
UK and US studies show that without the use of heat, there are no detectable traces of formaldehyde and acetaldehyde, two of the cancer-causing chemicals found in tobacco smoke and e-liquid vapour. The research also found no signs of eight other compounds identified as the main causes of smoking-related illness and disease.
“While addictive, nicotine when separated from heat is known to cause less harm,” said Mohammed Alshaiba Al Mazrouei, Chief Executive Officer of Medad Technology. “NEB Mist, the world’s first ultrasonic cavitation smoking alternative, is the only product registered under both the EU’s Tobacco Products Directive and the UK’s Medicines & Healthcare Products Regulatory Agency that produces no detectable carcinogens, including formaldehyde and acetaldehyde.”
The US Food and Drug Administration (FDA) has observed that e-cigarettes expose users to fewer harmful or potentially harmful chemicals than tobacco. It also found that their health benefits outweigh the risk of them attracting first-time users, particularly young people.
However, most e-cigarettes still release formaldehyde due to their heating process – approximately 20 micrograms (mcg) every 10 breaths compared to 120 mcg for standard cigarettes – a critical flaw NEB Mist has overcome thanks to its patented “misting” technology.
“By eliminating the harmful, heat-produced chemicals from regular cigarettes and e-cigarettes, we are reducing harm and improving the health of existing tobacco smokers, who are already consuming nicotine,” said Al Mazrouei of Medad Technology, which recently announced that it was investing U$150 million in ultrasound technology to support advances in smoking cessation and other medical treatments, as well as research in other industries.
“At the same time, we fully support efforts to reduce the amount of nicotine in both tobacco and alternative products, which explains why our NEB Mist e-liquid capsules, or Sonics, contain half the nicotine dose of the average e-cigarette,” he added. “We offer a variety of strengths as well as nicotine-free Sonics.”
Users aged 18 and above must verify their age in order to use the NEB Mist device, which must be activated online.
NEB Mist Sonics come with an integrated counterfeit protection chip, preventing the NEB Mist device being used with unauthorized capsules and e-liquids.
NEB Mist also has a built-in Bluetooth feature allowing users to connect to a dedicated mobile app to help monitor and reduce their nicotine intake. The NEB Mist app is the first of its kind to be approved on the Apple App Store in the UAE, UK, Europe, US and India, as well as the Google Play Store.
“While we will always encourage the reduction of nicotine consumption, we understand that quitting tobacco smoking can be an incredibly difficult task,” said Al Mazrouei.
“But by providing a credible smoking experience involving considerably less harm, our NEB Mist technology is potentially a game-changer for millions of smokers worldwide.”
Licensed by the Emirates Authority for Standardization and Metrology (ESMA), NEB Mist products are now on sale on nebmist.com and at Dalma Mall, Abu Dhabi.
About Medad Technology
Medad Technology is a privately owned and funded company dedicated to developing and investing in technologies that enhance public health and quality of life. Part of Medad Holding, it is pioneering initiatives in health-tech, biotech, fintech and power management.
Thanks to extensive investment in R&D over the past four years, Medad Technology has achieved breakthroughs in inhalation delivery systems based on patented ultrasound technology, with both medical and recreational applications. The company is also developing technologies under its biotech, fintech and power management divisions.
Medad Technology works as a group, with affiliates specializing in R&D, product development and pilot manufacturing. Together, its scientists, engineers and investors are building faster, smarter and safer solutions that will improve the health and quality of life of people around the world.